Abstract:Abstract Background Increasing germline gene mutations have been discovered in haematological malignancies with the development of next-generation sequencing (NGS), which is critical for proper clinical management and long-term follow-up of affected individuals. Tet methylcytosine dioxygenase 2 ( TET2 ) is one of the most common mutations in haematological neoplasms. We aimed to compare the clinical characteristics of patients with germline and somatic TET2 mutations in haematological diseases and to analyse whether germline TET2 mutations have a family aggregation and tumour predisposition. Methods Out of 612 patients who underwent NGS of 34 recurrently mutated genes in haematological diseases, 100 haematological patients with TET2 mutations were selected for further study. Somatic mutations were detected by NGS in bone marrow/peripheral blood genomic DNA (gDNA). Germline TET2 mutations were validated in nail/hair gDNA by Sanger sequencing. Digital data were extracted from the haematology department of the West China Hospital of Sichuan University. TET2 mutation results were analysed by referencing online public databases (COSMIC and ClinVar). Results One hundred patients were studied, including 33 patients with germline and 67 patients with somatic TET2 mutations. For germline TET2 mutations, the variant allele frequency (VAF) was more stable (50.58% [40.5–55], P < 0.0001), and mutation sites recurrently occurred in three sites, unlike somatic TET2 mutations. Patients with germline TET2 mutations were younger (median age 48, 16–82 years) ( P = 0.0058) and mainly suffered from myelodysplastic syndromes (MDS) ( n = 13, 39.4%), while patients with somatic TET2 mutations were mainly affected by acute myeloid leukemia (AML) ( n = 26, 38.8%) ( P = 0.0004). Germline TET2 mutation affected the distribution of cell counts in the peripheral blood and bone marrow ( P < 0.05); it was a poor prognostic factor for MDS patients via univariate analysis (HR = 5.3, 95% CI: 0.89–32.2, P = 0.0209) but not in multivariate analysis using the Cox regression model ( P = 0.062). Conclusions Germline TET2 mutation might have a family aggregation, and TET2 may be a predisposition gene for haematological malignancy under the other gene mutations as the second hit. Germline TET2 mutation may play a role in the proportion of blood and bone marrow cells and, most importantly, may be an adverse factor for MDS patients.

Germline Genomic Predisposition to Hematologic Malignancies

Germline Predisposition to Hematopoietic Malignancies: An Overview

Insights into the Molecular Mechanisms of Genetic Predisposition to Hematopoietic Malignancies: The Importance of Gene–Environment Interactions

Inherited Predispositions to Myeloid Neoplasms: Pathogenesis and Clinical Implications

Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome

Germline Predisposition for Clonal Hematopoiesis

Germline predisposition to clonal hematopoiesis

Genetic predisposition to myelodysplastic syndrome: Genetic counseling and transplant implications

Risk assessment and genetic counseling for hematologic malignancies—Practice resource of the National Society of Genetic Counselors

Germline genetic variants that predispose to myeloproliferative neoplasms and hereditary myeloproliferative phenotypes

Early detection and intervention of clonal hematopoiesis for preventing hematological malignancies

Update on pediatric cancer predisposition syndromes

Evaluation of the genetic basis of familial-associated early-onset hematologic cancers in an ancestral/ethnically diverse population

Comprehensive genomic characterization of hematologic malignancies at a pediatric tertiary care center

Molecular pathophysiology of germline mutations in acute myeloid leukemia

Prevalence and clinical implications of germline predisposition gene mutations in patients with acute myeloid leukemia

Germline Mutations of Renal Cancer Predisposition Genes and Clinical Relevance in Chinese Patients with Sporadic, Early‐onset Disease

Recent advances in pediatric hereditary neoplastic syndromes

Pedigree investigation, clinical characteristics, and prognosis analysis of haematological disease patients with germline TET2 mutation

Genome-first determination of the prevalence and penetrance of eight germline myeloid malignancy predisposition genes: a study of two population-based cohorts

Pathogenic Mutations in Cancer-Predisposing Genes: A Survey of 300 Patients with Whole-Genome Sequencing and Lifetime Electronic Health Records